<SEC-DOCUMENT>0001140361-25-007262.txt : 20250305
<SEC-HEADER>0001140361-25-007262.hdr.sgml : 20250305
<ACCEPTANCE-DATETIME>20250305210919
ACCESSION NUMBER:		0001140361-25-007262
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250305
DATE AS OF CHANGE:		20250305

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BridgeBio Pharma, Inc.
		CENTRAL INDEX KEY:			0001743881
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-38959
		FILM NUMBER:		25713364

	BUSINESS ADDRESS:	
		STREET 1:		3160 PORTER DR.
		STREET 2:		SUITE 250
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		(650) 391-9740

	MAIL ADDRESS:	
		STREET 1:		3160 PORTER DR.
		STREET 2:		SUITE 250
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BridgeBio Pharma LLC
		DATE OF NAME CHANGE:	20180618

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KKR Genetic Disorder L.P.
		CENTRAL INDEX KEY:			0001780408
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		C/O KOHLBERG KRAVIS ROBERTS & CO. L.P.
		STREET 2:		9 WEST 57TH STREET, SUITE 4200
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		(212) 750-8300

	MAIL ADDRESS:	
		STREET 1:		C/O KOHLBERG KRAVIS ROBERTS & CO. L.P.
		STREET 2:		9 WEST 57TH STREET, SUITE 4200
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001780408</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001743881</issuerCik>
<issuerName>BridgeBio Pharma, Inc.</issuerName>
<secFileNumber>001-38959</secFileNumber>
<issuerAddress>
<com:street1>3160 Porter Drive.</com:street1>
<com:street2>Suite 250</com:street2>
<com:city>Palo Alto</com:city>
<com:stateOrCountry>CA</com:stateOrCountry>
<com:zipCode>94304</com:zipCode>
</issuerAddress>
<issuerContactPhone>650 391-9740</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>KKR Genetic Disorder L.P.</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Affiliate</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>Goldman Sachs &amp; Co. LLC</name>
<address>
<com:street1>200 West Street</com:street1>
<com:city>New York</com:city>
<com:stateOrCountry>NY</com:stateOrCountry>
<com:zipCode>10282</com:zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>6000000</noOfUnitsSold>
<aggregateMarketValue>209820000</aggregateMarketValue>
<noOfUnitsOutstanding>190188626</noOfUnitsOutstanding>
<approxSaleDate>03/05/2025</approxSaleDate>
<securitiesExchangeName>NASDAQ</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<acquiredDate>07/01/2019</acquiredDate>
<natureOfAcquisitionTransaction>Conversion of Series B preferred units into shares of common stock (1)</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>15859312</amountOfSecuritiesAcquired>
<paymentDate>07/01/2019</paymentDate>
<natureOfPayment>Conversion of preferred units (1)</natureOfPayment>
</securitiesToBeSold>
<securitiesToBeSold>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<acquiredDate>07/01/2019</acquiredDate>
<natureOfAcquisitionTransaction>Conversion of Series C preferred units into shares of common stock (1)</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>8215295</amountOfSecuritiesAcquired>
<paymentDate>07/01/2019</paymentDate>
<natureOfPayment>Conversion of preferred units (1)</natureOfPayment>
</securitiesToBeSold>
<securitiesToBeSold>
<securitiesClassTitle>Common Stock</securitiesClassTitle>
<acquiredDate>07/01/2019</acquiredDate>
<natureOfAcquisitionTransaction>Conversion of Series D preferred units into shares of common stock (1)</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>10178954</amountOfSecuritiesAcquired>
<paymentDate>07/01/2019</paymentDate>
<natureOfPayment>Conversion of preferred units (1)</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<remarks>(1) Prior to the Issuer's initial public offering, KKR Genetic Disorder L.P. purchased 167,716,071 preferred units of BridgeBio Pharma LLC, the predecessor in interest to the Issuer, for aggregate consideration of $170,649,999.58 in a series of financing transactions. Upon completion of the reorganization of BridgeBio Pharma LLC into the Issuer, the preferred units held by KKR Genetic Disorder L.P. were converted into 34,253,561 shares of common stock of the Issuer for no additional consideration.</remarks>
<noticeSignature>
<noticeDate>03/05/2025</noticeDate>
<signature>KKR Genetic Disorder L.P., By: KKR Genetic Disorder GP LLC, its general partner, By: /s/ Ali Satvat, Vice President</signature>
</noticeSignature>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
